Keros Therapeutics initiated with an Outperform at Cowen

Cowen analyst Tyler Van Buren initiated coverage of Keros Therapeutics with an Outperform rating. The analyst says the company’s KER-050 and KER-012 improve upon Reblozyl and sotatercept, respectively. KER-050 has demonstrated more robust erythropoiesis across transfusion burden and ring sideroblasts status with a thrombopoiesis kicker, and updates this year could demonstrate superior durability, the analyst tells investors in a research note. The firm says significant value creation will occur in the shares if either drug works.